Topic
"Natural" does not mean "inert". Mushroom supplements have a small but real body of documented harm — and a large body of tolerability data. Both are collected here without marketing retouch.
Human mushroom safety is known from two different types of sources, and they should not be conflated:
The most notable signal is chaga and oxalate nephropathy: three published cases from Japan and Korea, all with biopsy-confirmed oxalate crystals in renal tubules. In one case the oxalate content of the chaga powder was measured directly — 14.2 g per 100 g, which at daily intake produced a load 2–5 times the usual dietary one. The common denominator of the cases: concentrated powder, grams a day, months and years.
The second class is drug interactions: maitake and INR elevation on warfarin (the Hanselin 2010 case), cautions on reishi and anticoagulants/immunosuppressants from the MSKCC database. The full map is in our article "Mushroom supplements and medicines".
Where safety was measured deliberately, the picture is reassuring: Phase I trials found no toxicity at working doses, and laboratory panels (liver, kidneys, blood) stayed within normal ranges. But these studies share a common limit: they are short (weeks to months) and run in specific groups — they say "at this dose, these people had no problems", not "safe always and for everyone".
Documented harm converges into one formula: concentrate + large dose + long duration + vulnerable system (kidneys, anticoagulation, immunosuppression). Culinary doses of mushrooms do not fall into this formula. Grams of chaga powder daily — falls into it squarely.
Clinical safety assessment of fermented Cordyceps cicadae mycelium: 49 participants took 1.05 g of lyophilized granules daily for 3 months. Blood analysis before and after showed no significant changes in kidney, liver, electrolyte or lipid markers; participants reported no adverse effects or complaints.
A Korean RCT in people with mild liver dysfunction (ALT 1.5–3× above normal): Cordyceps militaris extract 1.5 g/day vs. placebo with a full lab panel, liver CT and symptom scales. The preparation was tolerated safely — neither hematology nor biochemistry showed alarming shifts; the authors state protection against fatty-disease progression as a possibility, not a proven fact.
The best-documented harm from a "medicinal" mushroom: three published cases of oxalate nephropathy during regular chaga powder intake. Measured oxalate content in chaga — 14.2 g/100 g, exceeding ordinary dietary load 2–5×; outcomes range from reversible acute kidney injury to end-stage renal disease. A case-report format card — the canonical data type for safety.
The classic phase I 'how much can you take': women after chemo- and radiotherapy for breast cancer took turkey tail at 3, 6 or 9 g/day for six weeks. Of nine adverse events, seven were mild, one moderate, one severe; the preparation was judged tolerable up to 9 g/day. Incidental immune shifts were trends: lymphocyte rises at 6–9 g and NK-activity gains at 6 g/day.
Phase I in 78 cancer patients in remission: A. blazei granules at 1.8, 3.6 or 5.4 g/day for 6 months. Adverse events in 9 patients (12%) — mostly gastrointestinal (nausea, diarrhea); one case of liver dysfunction judged a food allergy. No dose dependence was found. The authors conclude general safety, apart from a possible allergic reaction.
A case report from Annals of Pharmacotherapy: a patient on a stable warfarin dose developed a rise in INR (a coagulation measure) after adding maitake extract. After the extract was stopped, INR returned to target. A single documented signal — but a clinically important one: anyone on anticoagulants should monitor INR when taking maitake.